This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Bio-tropin, human growth hormone, hGH, TevTropin, Tev-tropin, Tjet, ZOMA-Jet
Description: Tev-tropin binds to the human growth hormone receptor (GHR). Upon binding, tev-tropin causes dimerization of GHR, activation of the GHR-associated JAK2 tyrosine kinase, and tyrosyl phosphorylation of both JAK2 and GHR. These events recruit and/or activate a variety of signaling molecules that contribute to the GH-induced changes in enzymatic activity, transport function, and gene expression that ultimately culminate in changes in growth and metabolism.
Tev-tropin is administered through Antares' needle-free injector system, Tjet.
Deal Structure: Bio-Technology General is an Israeli subsidiary of Savient Pharmaceuticals. In September 1999, Bio-Technology General granted Teva Pharmaceuticals the exclusive marketing rights for hGH in the United States, effective July 2003. This was the time that the preliminary injuction relating to Genentechs patent that precludes Bio-Technology General from marketing bio-tropin in the United States was scheduled to expire. In March 2000, that agreement with Teva was amended and exclusive marketing rights for hGH in the United States were granted as of July 1, 2000. Part of a larger cooperation agreement to develop and market drugs, BTG is responsible for drug development and manufacture while Teva will distribute and market the products after regulatory approval. Upon execution of the agreement, a $10 million payment became due to BTG and was received in March 2000. BTG received a milestone payment of $2,500,000 in 2000 and will receive up to an additional $5,000,000 in milestone payments...See full deal structure in Biomedtracker
Partners: Teva Pharmaceutical Industries Ltd. Antares Pharma, Inc.
Additional information available to subscribers only: